Exploratory Study on the Role of Vitamin C in Promoting Health in Middle-Aged and Elderly Adults

Launched by PEKING UNIVERSITY THIRD HOSPITAL · Jan 20, 2025

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age: 55-65 years (for the experimental and control groups) or 18-70 years (for the baseline control group assessing aging changes).
• • Health Status: Deemed to be in good health based on medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring.
• • Weight: BMI within the range of 18.5-28 kg/m².
• • Informed Consent: Capable of signing the informed consent form and complying with the requirements and restrictions outlined in the study protocol.
• Exclusion Criteria:
• • Disease Status:Uncontrolled medical conditions or any disease that, in the investigator's opinion, may pose an inappropriate risk or contraindication or interfere with the study's objectives, conduct, or evaluation.Severe chronic or acute diseases (e.g., cancer, heart failure, renal insufficiency, COPD, diabetes, active liver disease, metabolic acidosis, poorly controlled hypertension, epilepsy, recent cardiovascular events, inflammatory bowel disease, neurological disorders, infectious diseases, severe autoimmune diseases, etc.).
• • Weight: BMI \< 18.5 or BMI \> 28.
• • Substance/Alcohol Abuse: Ongoing alcohol or drug abuse, or excessive alcohol consumption.
• • Medical History: History of gastrointestinal diseases, hyperuricemia, kidney or urinary tract stones, glucose-6-phosphate dehydrogenase deficiency, or paroxysmal nocturnal hemoglobinuria.
• • Allergy: Allergy to vitamin C or any component of its formulation.
• • Recent Medication Use: Use of high-dose vitamin C, vitamin E, low-dose aspirin, acarbose, metformin, NMN/NR, or other anti-aging/weight-loss drugs within the past 3 months.
• • Informed Consent: Inability to provide informed consent.
• • Other: Any physical condition that, in the investigator's opinion, may adversely affect the study process or outcomes.
• • Clinical Research Participation: Participation in any other clinical research within 3 months prior to screening or during the study period, or receipt of chemotherapy, radiotherapy, biologic therapy, small-molecule therapeutic agents, or investigational drugs, with incomplete recovery from related side effects (excluding alopecia or potential neuropathy).